Keryx Biopharmaceuticals (KERX) Phase 3 Study of Zerenex Meets Primary Endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/20/2026

1. TGT
2. EL
3. BILL
4. MRK
5. MRNA
6. ADI
7. LOW
8. TJX
9. DE
10. SPY

Go back to Keryx Biopharmaceuticals (KERX) Phase 3 Study of Zerenex Meets Primary Endpoint
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) Delayed: 3.36 --0 (-0%)
Previous Close $3.36    52 Week High $7.80 
Open $438.10    52 Week Low $2.80 
Day High $3.36    P/E N/A 
Day Low $3.36    EPS $-0.45 
Volume 1,132,646